Compositions for treating pathological calcification conditions, and methods using same
The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
1. A composition comprising a soluble ecto-nucleotide pyrophosphate/phosphodiesterase-1 (ENPP1) fusion polypeptide, wherein the soluble ENPP1 fusion polypeptide comprises a human ENPP1 polypeptide and a human serum albumin polypeptide, wherein the C-terminus of the human ENPP1 polypeptide is fused to the N-terminus of the human serum albumin polypeptide.
2. The composition of claim 1 , wherein the human ENPP1 polypeptide consists of amino acid residues 93 to 925 of SEQ ID NO: 15.
3. The composition of claim 1 , wherein the soluble ENPP1 fusion polypeptide consists of amino acid residues 23 to 1473 of SEQ ID NO: 22.
4. The composition of claim 1 , wherein the soluble ENPP1 fusion polypeptide consists of amino acid residues 93 to 1543 of SEQ ID NO: 21.
5. The composition of claim 1 , wherein the soluble ENPP1 fusion polypeptide is enzymatically active.